The Jerusalem PostNational Guardsman wounded in shooting near Capitol Hill, Washington, suspect arrestedInquirerResidents back Butuan seaport project, seek clear relocation planRTP DesportoPablo Rosario entusiasmado pelo reencontro com o PSVESPNEarly bets for Week 7: Three games to target right awayESPN Deportes¿Qué necesita Kimi Antonelli para ser campeón de F1 en el GP de Austin?Bollywood HungamaSonakshi Sinha and Zaheer Iqbal starrer Tu Hai Meri Kiran release put on hold by Bombay High Court over Rs 8.85 crores disputeZDF heuteEntdecken Sie das ZDF-NachrichtenstudioBusiness AMBelgië voert vanaf 1 november 2026 nieuw federaal kader tegen fraude en witwassen inFootball ItaliaBaldini: ‘The problem in Italian football isn’t the youth, it’s the directors’The South AfricanFour Springboks in doubt for the end-of-year tourSouth China Morning PostHouthi attack kills 53 at Yemen government training campIl Fatto QuotidianoNuovo allarme di Zelensky: “Starlink non funziona sui droni veloci”. L’esercito ucraino: gli alleati non ci avvisano sui missili balistici
KioskNews
The Daily Newsstand · Free, Always
Monday, October 19, 2026
Language
Seeking Alpha·United States·

UroGen gets FDA review for new bladder cancer therapy

Translate

Dulan Lokuwithana

FDA headquarters.FDA sign.wide.
  • UroGen Pharma (URGN) on Monday announced that the U.S. FDA accepted its marketing application for its new bladder cancer therapy, UGN-103, which is designed as a sustained-release version of the antitumor agent mitomycin.
  • The New Drug Application, based on results from the company’s Phase 3 UTOPIA trial, seeks the FDA approval of UGN-103 for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
  • The intravesical solution builds on the success of Zusduri, another mitomycin formulation UroGen (URGN) currently markets for adults with recurrent LG-IR-NMIBC. “UGN-103 combines our proprietary RTGel technology with a novel mitomycin formulation, which leverages a streamlined manufacturing process and simplified reconstitution,” CEO Liz Barrett said.
  • The FDA has assigned June 14, 2027, as the target action date for the NDA.

Recommended For You

Create Your Free Account to Keep Reading

Get the confidence to navigate an uncertain market with free breaking news and stock alerts.

View the original on Seeking Alpha →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.